We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
MiMedx Group Inc | NASDAQ:MDXG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -1.06% | 9.29 | 9.28 | 9.29 | 9.36 | 9.055 | 9.3021 | 193,146 | 19:56:05 |
Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys
MARIETTA, Ga., Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the placental biologics company. Caralyn Gargan, a former MiMedx employee, filed the action against MiMedx for "predatory sales practices" and "incentivized fraud, including Medicare fraud." Gargan also formally presented her answers and defenses to MiMedx's lawsuit which claimed that the 10 former employees, who recently left the company, allegedly breached their contractual obligations to MiMedx. The filing describes the MiMedx suit as a "blatant intimidation tactic."
Specifically, the counterclaims by Gargan allege that MiMedx "engaged in and has directed members of its sales team including [the former employee] to engage in, predatory sales practices aimed at increasing its revenue by incentivizing fraud on the United States government, including Medicare fraud."
The claims reference a warning letter issued by the FDA to MiMedx's CEO, Joseph H. Capper, concerning its AXIOFILL product on December 20, 2023, and assert that the former employee and others "became increasingly uncomfortable about MiMedx senior leadership's direction to sell AxioFill, even though it had not been approved by (or even submitted to) the FDA for FDA Premarket Approval."
The claims filed by Gargan's attorneys at Mintz and Fellows Labriola allege that she left MiMedx after "MiMedx tried to compel its employees to continue selling a product that the U.S. Food and Drug Administration ('FDA') determined could not lawfully be marketed without prior FDA approval."
Today's counterclaims come on the heels of another filed earlier this month on behalf of another former MiMedx employee, Lora Whooley. To read the Gargan claim please click HERE. To read the Whooley claim, please click here HERE.
View original content:https://www.prnewswire.com/news-releases/defendant-fights-back-against-mimedx-blatant-intimidation-non-compete-suit-302230456.html
SOURCE Mintz
Copyright 2024 PR Newswire
1 Year MiMedx Chart |
1 Month MiMedx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions